Basel Medical Group Ltd (BMGL)

Basel Medical Group Income Statement

Financials in millions SGD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Operating Revenue	11.32	10.05	9.7	10.66
Other Revenue	0.79	0.39	0.05	-
Revenue	12.11	10.44	9.75	10.66
Revenue Growth (YoY)	16.00%	7.08%	-8.55%	-
Cost of Revenue	8.92	5.89	5.58	2.72
Gross Profit	3.18	4.55	4.16	7.94
Selling, General & Admin	0.75	0.7	1.05	5.78
Other Operating Expenses	2.49	0.74	0.55	-0.31
Operating Expenses	4.42	1.97	2.16	5.48
Operating Income	-1.24	2.58	2	2.46
Interest Expense	-0.2	-0.18	-0.24	-0.32
Interest & Investment Income	0.08	-	0.3	0.25
Other Non Operating Income (Expenses)	-	-	0.07	-
EBT Excluding Unusual Items	-1.36	2.4	2.13	2.39
Impairment of Goodwill	-11.15	-	-	-
Pretax Income	-12.51	2.4	2.13	2.39
Income Tax Expense	-0.42	0.33	0.35	0.41
Earnings From Continuing Operations	-12.09	2.07	1.78	1.98
Minority Interest in Earnings	0	-	-	-
Net Income	-12.09	2.07	1.78	1.98
Net Income to Common	-12.09	2.07	1.78	1.98
Net Income Growth	-	16.23%	-9.84%	-
Shares Outstanding (Basic)	19	16	16	16
Shares Outstanding (Diluted)	19	16	16	16
Shares Change (YoY)	15.60%	-	-	-
EPS (Basic)	-0.64	0.13	0.11	0.12
EPS (Diluted)	-0.64	0.13	0.11	0.12
EPS Growth	-	16.23%	-9.84%	-
Free Cash Flow	-15.39	2.5	2.59	2.7
Free Cash Flow Per Share	-0.82	0.15	0.16	0.17
Gross Margin	26.29%	43.59%	42.71%	74.48%
Operating Margin	-10.23%	24.73%	20.55%	23.09%
Profit Margin	-99.84%	19.86%	18.30%	18.56%
Free Cash Flow Margin	-127.08%	23.97%	26.61%	25.37%
EBITDA	-1.13	2.61	2.03	2.48
EBITDA Margin	-9.35%	25.02%	20.86%	23.30%
D&A For EBITDA	0.11	0.03	0.03	0.02
EBIT	-1.24	2.58	2	2.46
EBIT Margin	-10.23%	24.73%	20.55%	23.09%
Effective Tax Rate	-	13.80%	16.34%	17.12%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q